Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Patent
1995-07-13
1998-12-01
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
4241331, 4241351, 4241431, 4241441, 4241521, 4241531, 4241561, 424 851, 424 852, A61K 39395, A61K 3819, A61K 3821
Patent
active
058434380
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The invention relates to the manipulation of hematopoietic stem cells. More particularly, the invention relates to methods for increasing the number of hematopoietic stem cells in peripheral blood.
BACKGROUND OF THE INVENTION
Hematopoietic stem cells are primitive, uncommitted progenitor cells that give rise to the lymphoid, myeloid and erythroid lineages of cells in blood. The stem cell population constitutes only a small proportion of the total cells in bone marrow and represents even a far more minuscule proportion of the cells in peripheral blood.
Stem cells have commonly been characterized by their surface antigenic determinants. Tsukamoto et al., U.S. Pat. No. 5,061,620 (1991), teaches that a highly stem cell concentrated cell composition is CD34.sup.+, CD10.sup.-, CD19.sup.- and CD33.sup.-. Leon et al., Blood 77:1218-1227 (1991), teaches that about one per cent of CD34.sup.+ cells, or about 0.01% of the total marrow cell population, do not express differentiation antigens, such as CD33 (myeloid lineage), CD71 (erythroid lineage) or CD10 and CD5 (lymphoid B and T lineage), and that reduced expression of CD34 expression during maturation is associated with increased expression of the differentiation antigens.
Combinations of antigenic and functional characteristics have also been used to characterize stem cells. Sutherland et al., Proc. Natl. Acad. Sci. U.S.A. 87:3584-3588 (1990), teaches that primitive stem cells do not bind to soybean agglutinin, express high levels of CD34, form blast colonies with high plating efficiency and are enriched in long-term culture initiating cells (LTC-IC). Craig et al., Blood Reviews 6:59-67 (1992), teaches that the CFU-GM assay is the most widely used measure of the hematopoietic progenitor viability of a bone marrow or peripheral blood stem cell harvest, and correlates well with per cent CD34.sup.+. Spangrude, Immunology Today 10:344-350 (1989), teaches that stem cells accumulate low levels of rhodamine 123 relative to other bone marrow cell types. Chaudhaury et al., Cell 66:85-94 (1991), teaches that stem cells express high levels of P-glycoprotein relative to other marrow cell types.
The ability to manipulate hematopoietic stem cells has become increasingly important in the development of effective chemotherapeutic and radiotherapeutic approaches to the treatment of cancer. Current approaches to chemotherapy and radiotherapy utilize bone marrow transplantation (BMT). BMT involves removing one to two liters of viable pelvic bone marrow containing stem cells, progenitor cells and more mature blood cells, treating the patient with chemotherapy or radiotherapy to kill tumor cells, and reintroducing bone marrow cells intravenously. BMT, however, suffers from many disadvantages. Harvesting of BM for BMT requires general anaesthesia, which increases both risk and cost. In addition, if cancer cells are present in the marrow and are not rigorously purged, recurrence of the disease is a distinct risk. Also, if widespread invasion of bone marrow by cancer cells (myeloma, Waldenstrom's macroglobulinemia) is present, peripheral blood cells are the only option for use in autologous transplantation (ABMT). Finally, patients who have undergone pelvic irradiation are not candidates for ABMT.
As a result of these difficulties, much interest has been developed in providing methods for obtaining stem cells from peripheral blood for autologous supply of stem cells to patients undergoing chemotherapy. Autologous supply of stem cells from peripheral blood would allow the use of greater doses of chemo- or radiotherapy, but with less risk than BMT. In addition, the use of stem cells from peripheral blood does not require anaesthesia to obtain the stem cells. Also, Lowry, Exp. Hematol. 20:937-942 (1992), teaches that cancer cells in the marrow tend not to peripheralize. The critical limitation in such a procedure, however, lies in the very small number of stem cells ordinarily present in peripheral blood. Lobo et al., Bone Marrow Transplantation 8:389-392 (1991),
REFERENCES:
patent: 5061620 (1991-10-01), Tsukamato et al.
patent: 5206345 (1993-04-01), Masinovsky
Pulido, J. Biol. Chem. 266:10241-10245, 1991.
Gillis "T-Cell-Derived Lymphokines" Ch 21 Fundamental Immunology pp. 621-638, 1989 Fundamental Immunology.
Bronchud et al., "In Vitro and In Vivo Analysis of the Effects of Recombinant Human Granulocyte Colony-Stimulating Factor in Patients", Br.J.Cancer, 58, pp. 64-69 (1988).
Bensinger et al., "Autologous Transplantation With Peripheral Blood Mononuclear cells Collected After Administration of Recombinant Granulocyte Stimulating Factor", Blood, 81, No. 11, pp. 31-58-3163 (1993).
Berenson, "Transplantation of CD34 + Hematopoietic Precursors: Clinical Rationale", Transplantation Proceedings, 24, No. 6, pp. 3032-3034 (1992).
Bregni et al., "Human Peripheral Blood Hematopoietic Progenitors Are Optimal Targets of Retroviral-Mediated Gene Transfer", Blood, 80, No. 6, pp. 1418-1422 (1992).
Brugger et al., "Ex Vivo Expansion of Enriched Peripheral Blood CD34 + Progenitor Cells by Stem Cell Factor, Interleukin-1.beta. (IL-1.beta.), IL-6, IL-3, Interferon-.gamma., and Erythropoietin", Blood, 81, No. 10, pp. 2579-2584 (1993).
Chao et al., "Granulocyte Colony-Stimulating Factor `Mobilized` Peripheral Blood Progenitor Cells Accelerate Granulocyte and Platelet Recovery After High-Dose Chemotherapy", Blood, 81, No. 8, pp. 2031-2035 (1993).
Craig et al., "Peripheral Blood Stem Cell Transplantation", Blood Review, 6:, pp. 59-67 (1992).
DePalma, "CellPro, Inc. Tests Its Stem Cell-Therapy in Clinic Trials", Genetic Engineering News, vol. 12 (May 1, 1992).
Denkers et al., "VLA Molecule Express May Be Involved in the Release of Acute Myeloid Leukaemic Cells From the Bone Marrow", Leukemia Research, 16, pp. 469-476 (1992).
Edgington, "New Horizons for Stem-Cell Bioreactors", Biotechnology, 10, pp. 1099-1106 (1992).
Gale et al., "Blood Stem Cell Transplants Come of Age", Bone Marrow Transplantation, 9, pp. 151-155 (1992).
Gerhartz, "Zukunftsperspektiven von Knochenmarkund Stammzellaktivierung fur die autologe Transplantation", Beitr Infusionther, 28, pp. 254-309 (1991).
Haas, "Successful Autologous transplantation of Blood Stem Cells Mobilized with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor", Exp. Hematol., 18, pp. 94-98 (1990).
Kessinger et al., "The Evolving Role of Autologous Peripheral Stem Cell Transplantation Following High-Dose Therapy for Malignancies", Blood, 77, No. 2, pp. 211-213 (1991).
Korbling, "Die Rolle der Stammzell-Mobilisation im Rahmen der Autologen Blutstammzell-Transplantation", Beitr. Infusionther., 28, 233-241 (1991).
Liesveld et al., "Expression of Integrins and Examination of Their Adhesive Function in Normal and Leukemic Hematopoietic Cells", Blood, 81, pp. 112-121 (1993).
Lobo et al., "Addition of Peripheral Blood Stem Cells Collected Without Mobilization Techniques to Transplanted Autologous Bone Marrow Did Not Hasten Marrow Recovery Following Myeloablative Therapy", Bone Marrow Transplantation, 8, pp. 389-392 (1991).
Magrin et al., "Collection, Processing and Storage of Peripheral Blood Stem Cells (PBSC)", Hematologica, 76, Suppl. 1, pp. 55-57 (1991).
Papayannopoulou et al., "Peripheralization of hemopoietic Progenitors in Primates Treated with Anti-VLA4 Integrin", Proc. Natl. Acad. Sci. USA, 90, pp. 9374-9378 (1993).
Rowe et al., "Hemopoietic Growth Factors: A Review", J. Clin.Pharmacol, 32, pp. 486-501 (1992).
Ryan et al., "Inhibition of Human Bone Marrow Lymphoid Progenitor Colonies by Antibodies to VLA Integrins", J.Immunol., 149, 11, pp. 3759-3764 (1992).
Siena et al., "Circulation of CD34 + Hematopoietic Stem Cells in the Peripheral Blood of High-Dose Cyclophosphamide-Treated Patients: Enhancement by Intravenous Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor", Blood, 74, No. 6, pp. 1905-1914 (1989).
Simmons et al., "Vascular Cell Adhesion Molecule-1 Expressed by Bone Marrow Stromal Cells Mediates the Binding of Hematopoietic Progenitor Cells", Blood, 80, 3
Board of Regents University of Washington
Johnson Nancy A.
Scheiner Toni R.
LandOfFree
Peripheralization of hematopoietic stem cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peripheralization of hematopoietic stem cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peripheralization of hematopoietic stem cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2393371